Labcorp

1) Strategic Growth and Leadership Initiatives - Labcorp reported a strong Q2 2026, with revenue growth of 6% to $3.7 billion and adjusted EPS growth of 15% to $4.99. - Key strategic initiatives included expanding specialty testing in oncology, neurology, autoimmune disease, and women's health, with double-digit revenue growth in these areas. - The company launched several innovative tests, including the FDA-approved ColoSense for colorectal cancer screening, enhancing patient access and early detection capabilities. - Partnerships with health systems and biopharmaceutical clients were strengthened, contributing to overall growth.

2) Financial Performance and Segment Results - Financial Metrics: | Metric | Q2 2026 | Q2 2025 | YoY Change | |--------------------------|--------------|--------------|--------------| | Revenue | $3.7 billion | $3.5 billion | +6% | | Adjusted EPS | $4.99 | $4.33 | +15% | | Free Cash Flow | $314 million | $543 million | -42% | | Adjusted Operating Margin | 15.8% | 15.1% | +70 bps |

• Diagnostics revenue grew 5.5% to $2.9 billion, while Biopharma Laboratory Services (BLS) revenue increased 6.5% to $836 million.
• Organic growth for Diagnostics was 3.6%, with volume growth contributing 3% and price mix 2.5%.
• BLS segment showed strong performance with a book-to-bill ratio of 1.14 for the quarter.

3) Challenges and Headwinds - The company anticipates a 30 basis point headwind from ACA-related changes, which is expected to impact less than 5% of total diagnostic volume. - Despite some pressure from patient responsibility and co-pays, Labcorp has not seen significant increases in bad debt, maintaining it in line with historical benchmarks.

4) Operational and Product Development Plans - Labcorp is focused on leveraging technology and innovation, including a collaboration with Epic to integrate over 6,500 diagnostic tests into their platform. - The consumer health segment is seeing strong growth, with Labcorp OnDemand achieving double-digit growth and the launch of the Marker genetic health panel. - The company is actively pursuing acquisitions to enhance its service offerings, with a robust pipeline of potential deals.

5) Guidance and Outlook - Labcorp raised its full-year guidance, expecting enterprise revenue growth of 5.4% to 6.3% and adjusted EPS of $18.10 to $18.55, implying growth of over 11% at the midpoint. - The company remains confident in its long-term growth trajectory, driven by strategic investments and operational efficiencies.

Bottom line: Labcorp's strong Q2 performance, driven by strategic growth in specialty testing and consumer health, positions the company well for continued success. With increased guidance and a focus on innovation, Labcorp is set to deliver sustainable growth and long-term value for shareholders.